Menu

Close

Sign InSign Out
ProductsOrderOrderSee allCo-pay cards & patient savings offersMaterialsSamples*Hospital products*Vaccines, biologics & small-molecule medicines**​​​​​​​​​​​​​​​​​​​​​Patient AssistancePatient AssistanceFind available assistance programsGo to Patient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore contentExplore contentExplore more contentEventsVideosMaterialsContactContactSee all contactPfizer corporateAsk a question

Menu

Close

AboutAboutBurden of IPDDosingDosingDosingAdministration and implementationEfficacy & Safety​​​​​​​Efficacy & SafetyEfficacySafety ProfileImmunogenicitySupport & Order​​​​​​​ Support & OrderVideosMaterialsOrder Prevnar 13®AdherenceResources

Resources

Vaccines are not 100% effective, and Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) will only help protect against serotypes in the vaccine. Help protect your patients with all 4 doses of the Prevnar 13® vaccine.


You can help increase adherence with the CDC-recommended vaccination schedule by using available resources in your practice

Contact your Pfizer Representative to request educational materials.

Call 1-844-439-2571 to request these
​​​​​​​resources from a representative Monday–Friday 8 AM - 5 PM EST

Reminder-recall systems have led to a 22% greater likelihood of children receiving CDC-recommended immunizations 1*

  * Evidence level: high quality. Evidence was deemed high quality based on the determination that further research is very unlikely to change the researchers’ confidence in the estimate of effect. The quality of the evidence was not downgraded since the previous analysis. No serious risk of bias, serious inconsistency, serious indirectness, or serious imprecision was identified among the 23 studies. However, one study was an outlier (RR 5.33).1

CDC=Centers for Disease Control and Prevention.

Useful Websites

The following websites are neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of these sites.

American Academy of Pediatrics
www.aap.org

American Academy of Family Physicians
www.aafp.org​​​​​​

American Nurses Association
www.nursingworld.org
​​​​​​​

Association for Early Learning Leaders
www.earlylearningleaders.org

Vaccinate Your Family
www.vaccinateyourfamily.org

The History of Vaccines
www.historyofvaccines.org

Immunization Action Coalition
www.immunize.org

Infectious Diseases Society of America
www.idsociety.org

National Association of Pediatric Nurse Practitioners
www.napnap.org

Society of Teachers of Family Medicine, Group on Immunization Education
www.stfm.org/Resources/Shots

Vaccines and Immunizations
www.cdc.gov/vaccines

Support & Order

  • Videos
  • Materials
  • Order Prevnar 13®
  • Adherence
  • Resources

Dosing

Review the CDC-recommended dosing schedule for Prevnar 13®

View now

Order from Pfizer Prime

To stock Prevnar 13®, call 1-800-666-7248 or click here

Order now

Register for PfizerPro

Support and services from Pfizer geared toward healthcare providers

Register now

References:
  1. ​​​​​​​Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, Asafu-Adjei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev. 2018;1:CD003941. doi:10.1002/14651858.CD003941.pub3.

PREVNAR 13 is a registered trademark of Wyeth LLC.
Manufactured by Wyeth Pharmaceuticals Inc.
© 2021 Pfizer Inc.
  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
  • In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
  • In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
  • In children 6 years through 17 years of age, Prevnar 13® is administered as a single dose

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for Prevnar 13®.

  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)​​​​​​​

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

IndicationS

  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F​​​​​​​​​​​​​​
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)
    ​​​​​​​

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine